CTLA4 and non-small cell lung carcinoma: The Cytotoxic T- lymphocyte-antigen 4 (CTLA-4), is another IC targeted by the inhibitory human antibody Ipilimumab, of particular success in clinical use for the treatment of metastatic melanoma [9,10] and for other solid tumors, such as non-small-cell lung cancer (NSCLC), and renal cell and prostate carcinomas [11].